UNIVERSITY of Queensland (UQ)researchers have announced the development of a vaccine delivery technology called NanoEmulsion that enables treatment to be tailored precisely for different types of cancer.
UQ's Professor Ranjeny Thomas said the technology had the potential to improve the precision of cancer immunotherapy, leading to better outcomes and reduced harmful side effects.
"Flexible cancer vaccines are a long-sought treatment strategy in cancer immunotherapy," Professor Thomas said.
"Cancer vaccines represent a precision cancer treatment strategy which stimulates the immune system to attack cancer cells without affecting other cells in the body," he added, noting that current cancer vaccines have limited flexibility and effectiveness.
NanoEmulsions are described as tiny carrier packages that encapsulate proteins made only by cancer cells.
In this way, they "educate the immune system about cancer proteins," Thomas explained.
The paper has been published in The Journal of Clinical Investigation.
CLICK HERE for access.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Apr 18
